



Dr. Cristina Suárez
Vall d'Hebron Institute of Oncology,
Barcelona, Spain

Dr. Cristina Suárez is a Medical Oncologist at Vall d'Hebron Institute of Oncology in Barcelona, Spain, and a lead investigator on the Phase III CheckMate -9ER trial and co-author of the CheckMate -9ER presentation being shared at ESMO 2020.

Dr. Suárez received her M.D. in Medicine and Surgery in 2001 at the Autonomous University of Barcelona, and received a Specialist Training in Medical Oncology at the Faculty of Medicine, Autonomous University of Barcelona, "Hospital del Mar – Parc de la Salut" of Barcelona.

In 2008, she joined the Oncology Department of Vall d'Hebron University Hospital as physician of the genitourinary program. In 2018, Dr. Suárez obtained "Cum Laude" qualification when she completed her studies of doctorate with the doctoral thesis, "Prognostic value of genetic alterations in the mTOR pathway of patients with metastatic renal cell carcinoma treated with mTOR inhibitors."

Dr. Suárez is principal investigator in several clinical trials related with genitourinary malignancies. She is also author and co-author of scientific papers, posters and both national and international book chapters, especially focused in the area of genitourinary tumors.

During the ESMO interviews, Dr. Suárez will be speaking to the challenges of managing kidney cancer, the unmet need in advanced renal cell carcinoma (aRCC)/metastatic renal cell carcinoma (mRCC) and the new hope the CheckMate -9ER data brings to people with cancer.